Floatz logo

Soquelitinib

Peripheral T-Cell Lymphoma, Not Otherwise Specified

Corvus Pharmaceuticals, Inc.Small moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

135 Active assets in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort.

Asset / SponsorPhaseRating
Inno-206
BeBetter Med Inc
Phase 4BBB
Pralatrexate
Peking University People's Hospital
Phase 4BBB
PREDNISONE TABLETS
Tarapeutics Science Inc.
Phase 4BBB
Cyclophosphamide
Tarapeutics Science Inc.
Phase 4BBB
(+)-VINCRISTINE
BeBetter Med Inc
Phase 4BBB

View all 50 →

Same molecule, other indications

Soquelitinib is also rated in:

T-cell non-Hodgkin lymphomaDormant
B
Indicative ·
62 / 100
View asset →
Nodal T-follicular helper cell lymphoma, follicular typeDormant
B
Indicative ·
60 / 100
View asset →
ALK-positive anaplastic large cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →